

The initial experience of COVID-19 vaccination from a tertiary care centre of India

RK Srivastava¹, Pranav Ish², Safdarjung COVID-19 Vaccination group*

¹Safdarjung Hospital, New Delhi; ²Department of Pulmonary, Critical Care and Sleep Medicine, VMMC and Safdarjung Hospital, New Delhi

Dear Editor,

Drugs Controller General of India (DCGI) has approved the Bharat biotech vaccine against COVID-19, which is a locally manufactured inactivated vaccine named ‘‘COVAXIN’’ in collaboration with the Indian council of medical research (ICMR) on 3rd January 2021 for emergency use along with the *Covishield* Oxford-AstraZeneca vaccine manufactured locally by the Serum Institute of India [1]. The phase 1 vaccine trial of Covaxin, which evaluated 375 patients in 4 groups and found pain at the injection site (5 %), headache (3 %), fatigue (3 %), fever (2 %), and nausea or vomiting (2 %) to be the most common adverse events following immunization (AEFI). All AEFI were mild (69%) or moderate (19 [31%]) and were more common after the first dose [2]. Thus, tolerable safety outcomes along with efficacy for the vaccine were suggested requiring further large-scale data. The phase 2 data revealed a favourable safety data [3], while the phase 3 trial data have not been published or made available yet [4]. The Government of India (GOI) launched a nationwide vaccination drive in a phased manner based on 16th January 2021 for health

care workers initially and subsequently extending to frontline workers, and the higher-risk population at designated sites in two doses 28 days apart [5].

The enrolment of beneficiaries was electronic and involved Co-WIN (COVID-19 Vaccine Intelligence Network), a cloud-based IT solution to prepare, implement, track, and evaluate COVID-19 vaccination in India extension of the existing electronic Vaccine Intelligence Network (eVIN) module. The system currently allows registration of beneficiaries (bulk upload), facilities/planning unit, and session sites accompanied by planning and scheduling sessions at the district level [6]. A list of 100 health care workers in the first week were released at each site which was stepped up to 500 in the fourth week. However, the turnaround was only around 50%, and hence walk-in vaccination was also started from 2nd week.

Till 16th February 2021 (*i.e.* one month after initiation), 1322 beneficiaries including doctors, nurses, support staff, and other health care workers, were vaccinated at our centre. It was a predominantly young population (mean age 42.78 years \pm 10. 2 years). One hundred twenty (9%) of these had comorbidities, with diabetes mellitus and hypertension being the predominant ones.

AEFI reported were minor and scanty, gradually the acceptance for vaccines increased and turnaround also [5]. An AEFI is defined as any untoward medical occurrence that follows immunization, which does not necessarily have a causal relationship with the vaccine’s usage. AEFI is categorically reported as minor, severe, or serious [7]. Minor AEFI are minor reactions which are common, self-limiting, *e.g.* pain and swelling at injection site, fever, irritability, malaise, *etc.* Severe AEFI are non-hospitalized cases with increased severity that do not lead to long-term problems but can be disabling, *e.g.* non-hospitalized cases of anaphylaxis that have recovered, high fever ($>102^{\circ}$ F), hypotonic hyporesponsive episodes, sepsis, *etc.* Serious AEFI includes deaths, hospitalizations, clusters, disability, media reports/community/parental concern following vaccination. The vaccination centre followed guidelines as per the protocol issued by GOI. The site is monitored by a multidisciplinary AEFI team; anaphylaxis kits, essential injectable drugs, defibrillator, ventilator, oxygen support and advanced vital monitors in the AEFI room. A 24-hour ambu-

Correspondence: Pranav Ish, Room #638, Superspeciality block, Department of Pulmonary, Critical Care and Sleep Medicine, VMMC and Safdarjung Hospital, New Delhi-110029, India.
Tel. +91 09958356000.
E-mail: pranavish2512@gmail.com.

Authors’ contributions: All the authors have read and approved the final version of the manuscript and agreed to be accountable for all aspects of the work.

Funding: None.

Conflict of interest: The authors declare no potential conflict of interests.

Informed consent: Written informed consent was obtained from all the patients involved in the present study.

Received for publication: 23 February 2021
Accepted for publication: 19 March 2021.

©Copyright: the Author(s), 2021
Licensee PAGEPress, Italy
Monaldi Archives for Chest Disease 2021; 91:1816
doi: 10.4081/monaldi.2021.1816

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

*Safdarjung COVID-19 Vaccination group:

KR Meena (Professor, Paediatrics), U Venkatesh (Assistant Professor, Community Medicine), Pushpa Kumari (Associate Professor, Medicine), Sonal Burman (Specialist, Medicine), Neeraj Kumar Gupta (Professor and Head, Pulmonary Medicine), Nitesh Gupta (Assistant Professor, Pulmonary Medicine), Rohit Kumar (Assistant Professor, Pulmonary Medicine), Swetabh Purohit (Senior resident, Pulmonary Medicine), Arjun Ramaswamy (Senior resident, Pulmonary Medicine)

Table 1. Adverse events following immunization after COVAXIN.

n	Age	Sex	Adverse effects	Day of onset	AEFI category	Treatment
1	30	Male	Fever for 2 days	1	Minor	Tab paracetamol
2	35	Female	Chest pain for 1 day	1	Minor	Tab diclofenac
3	35	Female	Local swelling of arm	1	Minor	Tab paracetamol
4	35	Female	Palpitation	1	Minor	Reassurance
5	41	Male	Headache for 1 day	1	Minor	Tab paracetamol
6	32	Male	Pain at injection site for 3 days	1	Minor	Tab paracetamol
7	60	Male	Myalgia/arthralgia for 3 days	2	Minor	Tab paracetamol
8	44	Male	Fever for 2 days	1	Minor	Tab paracetamol
9	41	Male	Headache, dizziness and vertigo for 1 day	2	Minor	Tab paracetamol
10	54	Female	Pain radiating to hand for 3 days	1	Minor	Tab diclofenac
11	48	Female	Vertigo for 2 days	1	Minor	Tab paracetamol
12	61	Female	Myalgia for 2 days	2	Minor	Tab paracetamol
13	64	Male	Fever for 1 day	1	Minor	Tab paracetamol
14	26	Female	Fever and rash on arm with itching for 3 days	1	Minor	Tab paracetamol Tab pheniramine
15	55	Male	Fever for 3 days	1	Minor	Tab paracetamol

lance along with a reserved bed in the Intensive care unit has also been earmarked.

At the authors' current centre, only 15 subjects developed an AEFI in one month. These AEFI were all after the first dose of vaccine as the second dose was started after this study period. The initial profile of the vaccinated people and the adverse events following immunization (AEFI) revealed a relatively safe vaccine (Table 1). Out of 15 reported AEFI, 8 were males. Twelve of the 15 AEFI were reported on day 1 after vaccination, while 3 were reported on day 2 after vaccination. All 15 minor reported AEFI were treated with tab paracetamol for fever, tab diclofenac for pain and reassurance.

To conclude, our initial experience is that COVAXIN is a safe and tolerable vaccine with minimal and minor side effect profile. There is need to build confidence and trust among the eligible beneficiaries so as to extend the benefit of vaccination to control the current pandemic.

The efficacy of COVAXIN can only be determined with a long-term follow-up and after the subjects receive a second dose of the vaccine.

References

1. Ministry of Health and Family Welfare. Press statement by the Drugs Controller General of India (DCGI) on restricted emergency approval of COVID-19 virus vaccine. Jan 3, 2021. Accessed: January 5, 2021. Available from: <https://pib.gov.in/PressReleaseDetail.aspx?PRID=1685761>
2. Ella R, Vadrevu KM, Jogdand H, et al. Safety and immunogenicity of an inactivated SARSCoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. *Lancet Infect Dis* 2021;21:39-51.
3. Ella R, Reddy S, Jogdand H, et al. Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report. *medRxiv* 2020.12.21. 20248643.
4. The Hindu [Internet]. Coronavirus. Covaxin efficacy is 81%, works against variants. Accessed: 18 March 2021. Available from: Downloaded from <https://www.thehindu.com/sci-tech/health/bharat-biotech-says-covid-19-vaccine-shows-81-interim-efficacy/article33980224.ece>
5. Government of India. Operational Guideline COVID-19 Vaccines [Internet]. New Delhi; 2021. Accessed: 22 February 2021. Available from: <https://www.mohfw.gov.in/pdf/COVID19VaccineOG111Chapter16.pdf>
6. The Times of India [Internet]. Covid-19: India vaccinates 54.7% healthcare workers registered on CoWin platform. Accessed: 22 February 2021. Available from: <https://timesofindia.indiatimes.com/india/covid-19-india-vaccinates-54-7-healthcareworkers-registered-on-cowin-platform/articleshows/80725869.cms>
7. WHO. Classification of AEFIS. Accessed: 22 February 2021. Available from: <https://vaccine-safety-training.org/classification-of-aefis.htm>